Wyeth execs get big roles in new Pfizer

Pfizer has opened the doors of top management to eight Wyeth execs. After the two companies merge, Wyeth types will serve in leadership roles from R&D to consumer health, with at least two reporting directly to Pfizer CEO Jeff Kindler.

One of those top two is Cavan Redmond, who now heads up Wyeth's consumer healthcare group; he'll be group president of Pfizer Diversified Businesses. The other is Mikael Dolsten (photo), Wyeth's research chief, who will lead Pfizer's new BioTherapeutics Research Group as president.

Ex-Wyethers will be president of specialty care and vaccines (Geno Germano) and president of vaccines (Jim Connolly). Wyeth's consumer healthcare chief, Cavan Redmond, will become group president of Pfizer Diversified Businesses, reporting directly to CEO Jeff Kindler (photo). Heading up consumer health for Pfizer--reporting to Redmond--will be Wyeth's Paul Sturman, and Wyeth's Erica Mann will be president of nutritional health. And two Wyeth research leaders will take over as chief scientific officers in charge of vaccine research and neuroscience research, respectively: Emilio Emini (photo) and Menelas Pangalos (photo).

"By putting together these businesses and combining in one team a number of strong and experienced Pfizer and Wyeth leaders," Kindler said in a statement, "we are creating the world's premier biopharmaceutical company--one that is powerfully positioned to provide substantial value for patients, customers, colleagues and shareholders."

Does the adoption of so many Wyeth managers mean that those farther down the Wyeth org chart might not suffer the lion's share of promised job cuts? Usually, it's the acquired company that loses the most workers in a merger, but In Vivo surmises that the $4 billion in cost savings are likely to be "more fairly distributed" with some Wyeth leaders in on the decision-making. But we'll have to wait to find out for sure.

- see the Pfizer release

Suggested Articles

Pfizer's diagnosis-focused launch strategy for Vyndaqel and Vyndamax is paying off with the meds reaching thousands of patients already.

Pfizer terminated a slew of trial cohorts testing Bavencio in combination with its own experimental drugs, as well as one monotherapy trial.

With its Eli Lilly-partnered Olumiant nearing filing in atopic dermatitis, Incyte's other JAK med Jakafi is also looking for a win in that indication.